-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Medical Crossfire: Bridging Expert Guidance and Evidence-Based Recommendations in the Treatment of AYA and Adult ALL

Sponsor: Amgen, Inc., Servier Pharmaceuticals, and Takeda Oncology
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Diseases, Therapies
Friday, December 8, 2023: 11:00 AM-2:00 PM
Marriott Grand Ballroom 11-13 (Marriott Marquis San Diego Marina)
Chair:
Elias Jabbour, University of Texas M.D. Anderson Cancer Ctr.
Disclosures:
Jabbour: Hikma Pharmaceuticals: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Research Funding; Ascentage Pharma Group: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Pfizer: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Adaptive Biotech: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Astex: Honoraria, Research Funding; Bristol-Myers Squibb: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding.
Speakers:
Lia Gore, MD, University of Colorado Cancer Center , Hagop M. Kantarjian, MD, University of Texas MD Anderson Cancer Center , Aaron C. Logan, MD, PhD, University of California San Francisco and Claire Roddie, MD, PhD, University College London
Disclosures:
Gore: Amgen: Consultancy; Novartis: Consultancy; Roche: Consultancy. Kantarjian: Shenzhen Target Rx: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Labcorp: Honoraria, Research Funding; KAHR medical: Honoraria, Research Funding; Ipsen Biopharmaceuticals: Honoraria, Research Funding; Curis: Honoraria, Research Funding; Biologix: Honoraria, Research Funding; Astellas: Honoraria, Research Funding; Ascentage: Honoraria, Research Funding; Amphista: Honoraria, Research Funding; Amgen: Honoraria, Research Funding; Abbvie: Honoraria, Research Funding; Stemline: Honoraria, Research Funding; Takeda: Honoraria, Research Funding; Daiichi-Sankyo: Research Funding; Immunogen: Research Funding; Jazz: Research Funding. Logan: AbbVie, Amgen, Actinium, BMS, Pfizer, Sanofi, Takeda: Consultancy; Amgen, Autolus Therapeutics, Kadmon, Kite, Pharmacyclics, Talaris: Research Funding.
Access Program Details

This Medical Crossfire® will provide an ideal format for the ALL care team to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda allowing them to review patient scenarios, reflect on how they might handle particular cases, integrate relevant evidence into real-world practice, and compare their patient care approaches with those of experts and peers. Faculty leading discussion of common clinical scenarios and solutions will discuss methods to best integrate the latest therapies into ALL treatment paradigms, address barriers to optimized integration of these novel agents, as well provide best practices for the management of adverse events.